December 2017 Newsletter
NEWSWORTHY
Asilomar Bio and Koch Biological Solutions Agree to Exclusive Commercial License of Leading Yield Enhancement Technology
Asilomar Bio: Travis Bayer (left) and Eric Davidson (right).  Photo: Clay Mitchell Farm.
QB3@953 startup, Asilomar has developed a small molecule to improve plant stress response. Koch Biological Solutions, LLC has secured exclusive global rights to commercialize and market products containing Asilomar Bio's flagship yield enhancement technology for foliar, in-furrow, and other modes of application on a broad set of crops, including all major row crops and plantation forestry. The patent-pending technology represents a new class of active ingredient, which enhances crop yield potential through a novel mode-of-action.  Full Press Release
NEWCOMERS
Engine Biosciences is a venture-backed technology company integrating experimental biology and data science to map and decipher complex biological networks for more effective and efficient drug discovery. Engine's technologies culminate from several years of research by our scientific founders who include faculty members of MIT, Harvard, Mayo Clinic, and UCSD, and our leadership team is applying our previous successful company building experiences to Engine to advance treatments to patients faster.
Applications of our broad platform have included rational combination therapy development, drug repurposing, novel drug discovery, and precision medicine enablement, some results of which have been published in leading peer-reviewed journals.  Engine is actively using its technology in a range of indications, through internal work and partnerships with Fortune 500 companies and leading research institutions, and is currently operating in the San Francisco Bay Area and in Singapore.
UPCOMING EVENTS
 
Office Hours: December 14, 2:00 - 3:30 PM Tosoh Hour 1. HPLC Products 2. Business Development and Venture Investment Our newest sponsor Tosoh will be here on December 14th. Amongst Tosoh's interests is the Separations and Purification Division.  Their scientist, Philip Hoang, will be here and would be happy to meet with you to discuss your purification challenges. He will be joined by Toshifumi Mogami and Kenichi Haga from Tosoh's Venture and Business Development Units. Tosoh is most interested in companies working in diagnostics and research tools.  Please contact Linda Eng if you'd like to meet with them. Toshifumi Mogami, PhD, is Vice President of Business Development & Venture Investment from Tosoh USA, Inc., the venture capital arm of Tosoh Corporation. Toshifumi has a background in biophysics and bioengineering. Kenichi Haga is Senior Vice President of Business Development and Venture Investment from Tosoh USA, Inc. and his background is in organic chemistry. Philip Hoang is an Account Manager of HPLC Columns for the West Coast. He is responsible for sales and support of HPLC/UHPLC columns in California, Oregon and Washington state. Philip received his bachelor's degree in biology from California State University, Long Beach. He has five years of technical experience in the HPLC and UHPLC field, where his work focused on the analysis of mAbs and ADCs.
OUR PARTNERS

December 2017 Newsletter



NEWSWORTHY

Asilomar Bio and Koch Biological Solutions Agree to Exclusive Commercial License of Leading Yield Enhancement Technology

Asilomar Bio: Travis Bayer (left) and Eric Davidson (right).  Photo: Clay Mitchell Farm.

QB3@953 startup, Asilomar has developed a small molecule to improve plant stress response. Koch Biological Solutions, LLC has secured exclusive global rights to commercialize and market products containing Asilomar Bio’s flagship yield enhancement technology for foliar, in-furrow, and other modes of application on a broad set of crops, including all major row crops and plantation forestry. The patent-pending technology represents a new class of active ingredient, which enhances crop yield potential through a novel mode-of-action.  Full Press Release

NEWCOMERS

Engine Biosciences is a venture-backed technology company integrating experimental biology and data science to map and decipher complex biological networks for more effective and efficient drug discovery. Engine’s technologies culminate from several years of research by our scientific founders who include faculty members of MIT, Harvard, Mayo Clinic, and UCSD, and our leadership team is applying our previous successful company building experiences to Engine to advance treatments to patients faster.
Applications of our broad platform have included rational combination therapy development, drug repurposing, novel drug discovery, and precision medicine enablement, some results of which have been published in leading peer-reviewed journals.  Engine is actively using its technology in a range of indications, through internal work and partnerships with Fortune 500 companies and leading research institutions, and is currently operating in the San Francisco Bay Area and in Singapore.

UPCOMING EVENTS

 
Office Hours: December 14, 2:00 – 3:30 PM
Tosoh Hour
1. HPLC Products
2. Business Development and Venture Investment

Our newest sponsor Tosoh will be here on December 14th. Amongst Tosoh’s interests is the Separations and Purification Division.  Their scientist, Philip Hoang, will be here and would be happy to meet with you to discuss your purification challenges. He will be joined by Toshifumi Mogami and Kenichi Haga from Tosoh’s Venture and Business Development Units. Tosoh is most interested in companies working in diagnostics and research tools.  Please contact Linda Eng if you’d like to meet with them.

Toshifumi Mogami, PhD, is Vice President of Business Development & Venture Investment from Tosoh USA, Inc., the venture capital arm of Tosoh Corporation. Toshifumi has a background in biophysics and bioengineering.

Kenichi Haga is Senior Vice President of Business Development and Venture Investment from Tosoh USA, Inc. and his background is in organic chemistry.

Philip Hoang is an Account Manager of HPLC Columns for the West Coast. He is responsible for sales and support of HPLC/UHPLC columns in California, Oregon and Washington state. Philip received his bachelor’s degree in biology from California State University, Long Beach. He has five years of technical experience in the HPLC and UHPLC field, where his work focused on the analysis of mAbs and ADCs.

OUR PARTNERS